Sponsor
Shanghai JMT-Bio Inc.
Clinical research sponsor
How to interpret these research links
Connected source recordsThe exact organization name Shanghai JMT-Bio Inc. appears in 18 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
18 shownA Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast CancerNCT07441460 · lead sponsor · 2026-03-06
RECRUITINGJMT106 Injection in the Treatment of Advanced Solid TumorsNCT07275073 · lead sponsor · 2025-09-25
RECRUITINGA Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIsNCT06829459 · lead sponsor · 2025-04-03
RECRUITINGJSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast CancerNCT06846437 · lead sponsor · 2025-02-18
RECRUITINGA Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive MutationsNCT06735391 · lead sponsor · 2024-10-23
RECRUITINGA Study of JMT203 in Patients With Cancer CachexiaNCT06868849 · lead sponsor · 2024-05-15
RECRUITINGEfficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.NCT05838066 · lead sponsor · 2023-07-23
RECRUITINGEvaluate the Safety and Tolerability of Multiple Doses of JMT206 Injection in Obese ParticipantsNCT07840729 · lead sponsor · 2026-10-20
NOT_YET_RECRUITINGA Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast CancerNCT07545044 · lead sponsor · 2026-05-30
NOT_YET_RECRUITINGSYS6090 Combination Therapy in Advanced Lung CancerNCT07472647 · lead sponsor · 2026-02-28
NOT_YET_RECRUITINGGlumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer PatientsNCT06908772 · lead sponsor · 2025-04-01
NOT_YET_RECRUITINGA Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast CancerNCT06747338 · lead sponsor · 2024-12-16
ACTIVE_NOT_RECRUITINGEfficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung CancerNCT06319313 · lead sponsor · 2024-05-01
NOT_YET_RECRUITINGJMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins MutationsNCT06380348 · lead sponsor · 2024-04-26
NOT_YET_RECRUITINGReal-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung CancerNCT05513664 · lead sponsor · 2022-09-01
UNKNOWNJMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common MutationsNCT06391944 · lead sponsor · 2021-11-21
ACTIVE_NOT_RECRUITINGEfficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung CancerNCT05132777 · lead sponsor · 2021-11-20
UNKNOWNEfficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung CancerNCT04448379 · lead sponsor · 2020-06-29
UNKNOWNDrugs studied in this sponsor's trials
12 mapped RxNorm conceptsThese drug records are connected through ClinicalTrials.gov studies listing Shanghai JMT-Bio Inc. as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.
docetaxel5
pertuzumab4
trastuzumab4
carboplatin2
osimertinib2
cisplatin Injection1
cyclophosphamide1
doxorubicin1
docetaxel RxCUI 72962 · Lead sponsor in 5 linked trial(s) · 2 currently recruiting
5 trials
pertuzumab RxCUI 1298944 · Lead sponsor in 4 linked trial(s) · 2 currently recruiting
4 trials
trastuzumab RxCUI 224905 · Lead sponsor in 4 linked trial(s) · 2 currently recruiting
4 trials
carboplatin RxCUI 40048 · Lead sponsor in 2 linked trial(s) · 1 currently recruiting
2 trials
osimertinib RxCUI 1721560 · Lead sponsor in 2 linked trial(s) · 1 currently recruiting
2 trials
cisplatin Injection RxCUI 1736853 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
cyclophosphamide RxCUI 3002 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting
1 trial
doxorubicin RxCUI 3639 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting
1 trial
epirubicin RxCUI 3995 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting
1 trial
osimertinib mesylate RxCUI 1721559 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting
1 trial
pemetrexed RxCUI 68446 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting
1 trial
pemetrexed Injection RxCUI 1728071 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
Sponsor roles
lead sponsor18
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.